Sunovion schizophrenia study yields dosage answers
Sunovion is headquartered in Marlborough.
Marlborough drug maker Sunovion Pharmaceuticals announced positive results Monday for dosing increases while using Latuda in treating people with schizophrenia from a study investigating dosage for the drug.
The study, published in the Journal of Clinical Psychiatry, set out to examine dosage for the drug in treating people with schizophrenia, determining not only a base dosage (40 milligrams per day) but finding that the dosage could be increased up to 160 mg per day for those who did not respond to lower dosages, according to a release from Sunovion.
“In the treatment of patients with schizophrenia, an important clinical concern is how to address early non-response to therapy,” said study co-author Dr. John Kane, chairman of the Department of Psychiatry at The Zucker Hillside Hospital in Glen Oaks, N.Y., in a statement. “These study data provide clinically important evidence to inform decisions about when to increase medication dosage.”
The study found the drug was generally well tolerated, according to the release. Latuda is approved by the U.S. Food and Drug Administration to treat adult patients with major depressive episodes associated with bipolar I disorder and schizophrenia.
WBJ Web Partners
Most Recent
Most Recent
0 Comments